GHRH analog
A growth hormone releasing hormone analog that prompts your pituitary to produce GH rather than replacing it.
Sermorelin is a shortened version of growth hormone releasing hormone, the signal your hypothalamus sends to the pituitary to release growth hormone. It was FDA-approved for pediatric growth hormone deficiency diagnosis and treatment before being withdrawn from the US market for commercial rather than safety reasons, and it remains widely available through compounding pharmacies.
There are two ways to raise growth hormone: inject the hormone itself, or ask your pituitary to make more. Sermorelin does the second. The practical advantage is that your body's feedback loops stay intact — the pituitary releases GH in its natural pulsatile pattern and stops when signals say to stop, which is much harder to overshoot than direct injection.
Sermorelin comprises the first 29 amino acids of GHRH, the portion carrying full biological activity. It binds pituitary GHRH receptors, stimulating synthesis and pulsatile release of endogenous growth hormone, which in turn raises hepatic IGF-1. Because release remains subject to somatostatin feedback, physiological pulsatility and the negative feedback ceiling are preserved. Plasma half-life is short — roughly 10 to 20 minutes — and it is typically administered at night to align with the natural nocturnal GH pulse.
Sleep quality changes, when they occur, are usually the first thing reported and appear within a few weeks. Body composition effects, if any, take months and are modest. Anyone expecting the effects associated with supraphysiologic growth hormone will be disappointed, which is arguably the point.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
The safety profile is generally regarded as favorable and better than exogenous growth hormone, precisely because it preserves feedback control. Injection site reactions and flushing are the common complaints. Not currently FDA-approved in the US, though available through compounding. Contraindicated in active malignancy given the IGF-1 relationship, and caution is warranted with diabetes since GH affects insulin sensitivity. Prohibited in sport. Not appropriate during pregnancy or breastfeeding.
Compounding pharmacy product with a prescription is a genuinely different supply chain from research-grade material. If you qualify for the former, it is the better route.
It is generally considered so, because it preserves the feedback loop that prevents overshooting. That safety comes with a correspondingly smaller effect.
It was approved for pediatric use and later withdrawn from the US market for commercial reasons. It remains available through compounding pharmacies.
Both are GHRH analogs. Tesamorelin is longer-acting, currently FDA-approved for a specific indication, and considerably more expensive.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation